Dermatology · Phoenix area, AZ
Dermatology and skin studies in Phoenix area, AZ
24 recruiting studies have a site in the Phoenix area. This page includes nearby cities such as Scottsdale, Tempe, Mesa, Chandler.
24 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 2
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
Oruka Therapeutics, Inc.
- Location
- Phoenix, AZ + 22 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
Nektar Therapeutics
- Location
- Phoenix, AZ + 18 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 2
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Sanofi
- Location
- Scottsdale, AZ + 19 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
Takeda
- Location
- Chandler, AZ + 45 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
Sanofi
- Location
- Phoenix, AZ + 16 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Bristol-Myers Squibb
- Location
- Phoenix, AZ + 90 other US sites
- Eligibility basics
- Ages 40+
- RecruitingPhase 2
A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
Pfizer
- Location
- Phoenix, AZ + 13 other US sites
- Eligibility basics
- Ages 18–64
- RecruitingPhase 3
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Incyte Corporation
- Location
- Phoenix, AZ + 73 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
Incyte Corporation
- Location
- Phoenix, AZ + 15 other US sites
- Eligibility basics
- Ages 12–75
- RecruitingPhase 2
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Incyte Corporation
- Location
- Phoenix, AZ + 23 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 2
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Eli Lilly and Company
- Location
- Phoenix, AZ + 17 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU…
Celldex Therapeutics
- Location
- Scottsdale, AZ + 24 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
Janssen Research & Development, LLC
- Location
- Glendale, AZ + 20 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis
Vanda Pharmaceuticals
- Location
- Glendale, AZ + 9 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
Incyte Corporation
- Location
- Phoenix, AZ + 65 other US sites
- Eligibility basics
- Ages 2–11
- RecruitingPhase 2
Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis
Beijing InnoCare Pharma Tech Co., Ltd.
- Location
- Phoenix, AZ + 13 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
Eli Lilly and Company
- Location
- Scottsdale, AZ + 28 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 4
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice…
Eli Lilly and Company
- Location
- Phoenix, AZ + 38 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
Apollo Therapeutics Ltd
- Location
- Phoenix, AZ + 24 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 1/Phase 2
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne
Sanofi Pasteur, a Sanofi Company
- Location
- Scottsdale, AZ + 78 other US sites
- Eligibility basics
- Ages 18–45
- RecruitingPhase 2
A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
Navigator Medicines, Inc.
- Location
- Phoenix, AZ + 13 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 1
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
UCB Biopharma SRL
- Location
- Peoria, AZ + 29 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
Sun Pharmaceutical Industries, Inc.
- Location
- Scottsdale, AZ + 53 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars
AbbVie
- Location
- Glendale, AZ + 9 other US sites
- Eligibility basics
- Ages 22+
Who these studies look for
Most require an active, diagnosed skin condition of a certain severity and a pause on some current treatments before starting.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.